Navigation Links
Blue Cross Blue Shield of North Carolina Implements Aggressive Generic Medication Campaign
Date:4/16/2008

The Plan Moves More than 40 Tier 3 Drugs for Chronic Diseases to Tier 2,

According to a New Report from HealthLeaders-InterStudy

NASHVILLE, Tenn., April 16 /PRNewswire/ -- HealthLeaders-InterStudy, the leading provider of managed care market intelligence, reports that Blue Cross and Blue Shield of North Carolina has begun an aggressive generic medication campaign as of January 2008 in which it waives the copayment on all generic drugs that treat congestive heart failure, high blood pressure, high cholesterol and diabetes. According to the new report entitled Blue Profiler: Blue Cross and Blue Shield of North Carolina, the campaign, called Medication Dedication, is the plan's attempt to encourage members to take prescription drugs as directed and to make the overall cost of drugs more affordable.

"In 2007, Blue Cross and Blue Shield of North Carolina's generic utilization rate was higher than its two major competitors, UnitedHealthcare and CIGNA Healthcare," said Heather Wicks, analyst at HealthLeaders- InterStudy. "The Blue Plan's rate was 58 percent in 2007, up from 46.8 percent in 2004."

The report also finds that Blue Cross and Blue Shield of North Carolina has moved more than 40 drugs to treat chronic diseases from Tier 3 to Tier 2 as part of its Medication Dedication program. For example, Tier 3 drugs to treat diabetes moved to Tier 2 status include Byetta, Fortamet, Glucagen, Glumetza, Glyset, Prandin, Riomet, Starlit and Symlin.

"Blue Cross Blue Shield of North Carolina had been more aggressive than competitors CIGNA Healthcare and UnitedHealthcare in the placement of more expensive brand-name drugs in tiers requiring higher copays," continued Ms. Wicks. "However, the decision to move more drugs to lower tiers in 2008 should put Blue Cross Blue Shield of North Carolina more in line with other payers."

Blue Profiler: Blue Cross and Blue Shield of North Carolina is one of 15 2008 Blue Profiler reports on the nation's largest nonprofit Blue Cross Blue Shield plans, which together insure more than 50 million people.

About Blue Profiler

Blue Profiler offers the most comprehensive analysis of the nonprofit Blue Cross Blue Shield plans. Each report includes an individual nonprofit Blue plan and includes valuable analysis that will allow companies to more effectively partner with these dominant organizations. Each report includes information on:

-- Competitive analysis

-- Enrollment trends

-- Company-wide financials

-- HMO financials

-- Consumer-driven products

-- Medicare strategy

-- Pharmacy

-- Disease Management

About HealthLeaders-InterStudy

HealthLeaders-InterStudy (http://www.hl-isy.com) is the authoritative source for managed care data and analysis. HealthLeaders-InterStudy is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE HealthLeaders-InterStudy
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Using HR Performance Metrics to Drive Costs Down Across HR Functions
2. Cedar Point to Host 17th Annual Red Cross Miniature Golf Event
3. Two Men to Walk Across America for Autism Aid, Awareness, and Loving Memory of Young Boy
4. Polar Introduces Cost-Effective Solution to Reduce Heart Rate Data Cross-Talk
5. Kids With Cell Phones Not as Safe Crossing Streets
6. Blue Cross and Blue Shield of Oklahoma Launches an Integrated Medical-Dental Health Program
7. Anthem Blue Cross Tackles Childhood Obesity in California Through Free BMI Workshops for Pediatric and Family Medicine Health Care Providers
8. Business Leader, Nonprofit Volunteer to Head the American Red Cross
9. Researchers Able to Continue their Work to Help Patients Thanks to McDevitt Excellence in Research Awards from Blue Cross Blue Shield of Michigan Foundation
10. Daniel Corcoran named President of Anthem Blue Cross and Blue Shield in Maine
11. Partnership for Prescription Assistance Celebrates Three Year Anniversary; Helps Nearly 5 Million Uninsured Patients Across United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month ... bleeding gums in Vancouver, BC, may be developing gingivitis, the first stage of ... and diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants in the ... finding product improvements that could reduce the occurrence of unplanned extubations (UEs). ... breathing or to provide medication. Sometimes, patient movement can cause unplanned extubations which ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage ... featuring seven new products designed to create tailored looks and athleisure-inspired outfits. UA Flex ... cotton easy care stretch twill. , With trendy looks hitting the medical community, UA ...
(Date:6/20/2017)... ... , ... John D'Eri, CEO of Rising Tide Car Wash , will ... during the Autism Society of America 's 49th annual conference to be held ... (DJFF) was founded in 2002 as the nation's first autism organization focused exclusively ...
(Date:6/20/2017)... ... June 20, 2017 , ... International water ... The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health ... world’s water crisis and how it affects the human eyes. , According ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. ... focused on the design, manufacture, sale and distribution of ... on the progress of its commercial roll-out in ... available in more than one hundred (100) medical institutions ... AeroForm offers a needle-free alternative for women who ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: